Grifols SA
OZTA
Company Profile
Business description
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Contact
Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935712200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,554
Stocks News & Analysis
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
stocks
Chart of the week: Did ASX companies underwhelm or impress during earnings season?
The Chart of the Week looks at how our Fair Values changes for Australian companies during earnings season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,966.60 | 36.00 | -0.45% |
| CAC 40 | 7,946.97 | 41.99 | -0.53% |
| DAX 40 | 22,523.35 | 153.06 | -0.67% |
| Dow JONES (US) | 41,062.19 | 288.74 | -0.70% |
| FTSE 100 | 8,525.21 | 15.76 | -0.18% |
| HKSE | 23,462.65 | 137.66 | -0.58% |
| NASDAQ | 17,429.04 | 219.41 | -1.24% |
| Nikkei 225 | 36,790.03 | 29.06 | -0.08% |
| NZX 50 Index | 12,209.05 | 40.50 | -0.33% |
| S&P 500 | 5,556.50 | 42.80 | -0.76% |
| S&P/ASX 200 | 7,749.10 | 37.10 | -0.48% |
| SSE Composite Index | 3,358.73 | 13.20 | -0.39% |